BioSpace News Archive

HUTCHMED Limited announces that its New Drug Application for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration.

Innovent Biologics, Inc. announced the updated results of IBI351 from a phase 1 clinical trial in an oral presentation at the 2023 American Association for Cancer Research Annual Meeting.

Lucid Diagnostics Inc. announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today presented preclinical data characterizing MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader designed for the treatment of MYC-driven solid tumors, including lung cancer.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023, after the market close.

Boomerang Medical has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use of nerve stimulation as a potential treatment for Crohn’s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease.

Glucose monitoring is a key link in diabetes management. Currently, there are two main methods for self-monitoring of glucose in patients with diabetes, one is the traditional blood glucose Monitoring, and the other is continuous glucose monitoring.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the execution of an asset purchase agreement for the acquisition of ARS Pharmaceutical’s Nectin-4 antibody.